Trials / Recruiting
RecruitingNCT07242469
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-1403 + additive coformulation | MK-1403 + additive coformulation is a co-formulated product of MK-1403 administered orally. |
| DRUG | Placebo + additive coformulation | Placebo + additive coformulation is a co-formulated product of placebo administered orally. |
Timeline
- Start date
- 2025-12-22
- Primary completion
- 2026-08-28
- Completion
- 2026-08-28
- First posted
- 2025-11-21
- Last updated
- 2026-01-14
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07242469. Inclusion in this directory is not an endorsement.